Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Jeffrey R. Huminik"'
Autor:
Nicholas G. Nickols, Matthew B. Goetz, Christopher J. Graber, Debika Bhattacharya, Guy Soo Hoo, Matthew Might, David B. Goldstein, Xinchen Wang, Rachel Ramoni, Kenute Myrie, Samantha Tran, Leila Ghayouri, Sonny Tsai, Michelle Geelhoed, Danil Makarov, Daniel J. Becker, Jun-Chieh Tsay, Melissa Diamond, Asha George, Mohammad Al-Ajam, Pooja Belligund, R. Bruce Montgomery, Elahe A. Mostaghel, Carlie Sulpizio, Zhibao Mi, Ellen Dematt, Joseph Tadalan, Leslie E. Norman, Daniel Briones, Christina E. Clise, Zachary W. Taylor, Jeffrey R. Huminik, Kousick Biswas, Matthew B. Rettig
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-8 (2021)
Abstract Background Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface protease. Pre-clinical an
Externí odkaz:
https://doaj.org/article/62f781dbd78244d99ccb944f53f3ca94
Autor:
Zhibao Mi, Jun-Chieh Tsay, Zachary W Taylor, Sonny Tsai, Daniel Briones, Christina E. Clise, R. Bruce Montgomery, Michelle Geelhoed, Matthew Bidwell Goetz, Leila Ghayouri, Jeffrey R Huminik, Carlie Sulpizio, Rachel Ramoni, Guy W. Soo Hoo, Xinchen Wang, Kousick Biswas, David Goldstein, Nicholas G. Nickols, Danil V. Makarov, Kenute Myrie, Melissa Diamond, Mohammad Al-Ajam, Matthew Rettig, Christopher J. Graber, Debika Bhattacharya, Joseph Tadalan, Matthew Might, Samantha Tran, Asha George, Elahe A. Mostaghel, Leslie E Norman, Pooja Belligund, Daniel J. Becker, Ellen DeMatt
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-8 (2021)
Trials
Trials
Background Therapeutic targeting of host-cell factors required for SARS-CoV-2 entry is an alternative strategy to ameliorate COVID-19 severity. SARS-CoV-2 entry into lung epithelium requires the TMPRSS2 cell surface protease. Pre-clinical and correla
Autor:
Conor McBurney, Todd A. Conner, Robert J. Anderson, Douglas Lammie, Rajiv Agarwal, Ian Craig, Jeffrey R Huminik, Nicholas V. Emanuele, Grant D. Huang, Domenic J. Reda, David J. Leehey, James S. Kaufman, Linda Polzin, Kimberly Carlson, Christina E. Clise
Publikováno v:
BMJ Open
BMJ Open, Vol 11, Iss 8 (2021)
BMJ Open, Vol 11, Iss 8 (2021)
IntroductionDiabetic kidney disease (DKD) is the most frequent cause of end-stage renal disease (ESRD) in the USA and worldwide. Recent experimental and clinical data suggest that the non-specific phosphodiesterase inhibitor pentoxifylline (PTX) may